Search

Displaying results 3971 - 3980 of 5895 in total
  1. Drug

    Coronavirus-Like Particle COVID-19 Vaccine

    go.drugbank.com/drugs/DB15852
    Experimental

    In July 2020, Medicago partnered with Dynavax to test the vaccine with its adjuvant, Cpg 1018 (also known as [ISS-1018]), meant to provide an enhanced immune response to the vaccine. … In addition, Medicago partnered with GlaxoSmithKline (GSK) to test its adjuvant, AS03.

  2. Drug

    Altropane I-123

    go.drugbank.com/drugs/DB15144
    Investigational

    Altropane I-123 is under investigation in clinical trial NCT01950468 (A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the

  3. Drug

    Brotizolam

    go.drugbank.com/drugs/DB09017
    ApprovedWithdrawn

    Brotizolam has similar effects to short-acting benzodiazepines such as triazolam. Brotizolam is indicated for 2-4 weeks of treatment for severe or debilitating insomnia.

    Products: BROTIZOLAM DOC GENERICI
  4. Drug

    AEG35156

    go.drugbank.com/drugs/DB06184
    Investigational

    This agent reduces total levels of XIAP in tumor cells, working synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis. … XIAP interferes with both the intrinsic and extrinsic program-death signaling pathways, which may render tumor cells resistant to apoptosis.

  5. Drug

    GSK-923295

    go.drugbank.com/drugs/DB06097
    Investigational

    GSK-923295 is the first drug candidate to enter human clinical trials that specifically targets CENP-E and is currently in Phase I human clinical trials being conducted by GSK. … GSK-923295 is a small-molecule inhibitor of the mitotic kinesin centromere-associated protein E (CENP-E), and the third novel drug candidate to arise from Cytokinetics' broad strategic alliance with GlaxoSmithKline

  6. Drug

    Alectinib

    go.drugbank.com/drugs/DB11363
    ApprovedInvestigational

    Approved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance

  7. Drug

    Inositol 1,3-bisphosphate

    go.drugbank.com/drugs/DB02942
    Experimental

    It is an experimental compound with no approved therapeutic indications. … The compound corresponds to the soluble headgroup of phosphatidylinositol 3-phosphate (PtdIns(3)P), an endosomal signaling lipid recognized by FYVE domains, and it has been used as a ligand in structural

  8. Drug

    Picoplatin

    go.drugbank.com/drugs/DB04874
    Investigational

    It causes apoptosis (cell death) by binding to DNA and interfering with DNA replication and transcription.

  9. Drug

    Succinobucol

    go.drugbank.com/drugs/DB05399
    Investigational

    AGI-1067, is a novel small molecule with anti-oxidant and anti-inflammatory properties that was discovered by AtheroGenics and designed to treat atherosclerosis of the blood vessels of the heart, or coronary

  10. Drug

    EDP1815

    go.drugbank.com/drugs/DB16486
    Investigational

    EDP1815, was investigated in several clinical trials (NCT05066373, NCT05439941, NCT05682222, NCT03733353, NCT04603027, NCT04488575, NCT05121480, NCT04393246) to evaluate its safety and efficacy in conditions